# High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

> **NCT05038228** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban
- **DRUG:** Dabigatran
- **DRUG:** Vitamin K antagonist (VKA)

## Key facts

- **NCT ID:** NCT05038228
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2026-04-08
- **Final completion:** 2026-04-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038228, "High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05038228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*